Skip to main content

Endometrial Cancer Clinical Trials

Review the endometrial cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 171

Sacituzumab Govitecan in Combination with Cisplatin for the Treatment of Patients with Recurrent Platinum-sensitive Ovarian or Endometrial Cancer
Status: Active
Location: 3 locations
Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic and Prostate Cancers
Status: Active
Location: 3 locations
Study of INCB123667 in Subjects With Advanced Solid Tumors
Status: Active
Location: 3 locations
Avelumab with M1774 for the Treatment of Patients with ARID1A-Mutated Recurrent Endometrial Cancer who have Received Prior Immunotherapy
Status: Active
Location: 2 locations
Azenosertib for the Treatment of Women with Recurrent or Persistent Uterine Serous Carcinoma
Status: Active
Location: 2 locations
Afatinib in Treating Patients with Recurrent Stage I-IV HER2 Positive Uterine Cancer
Status: Active
Location: 2 locations
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Status: Active
Location: 4 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Status: Active
Location: 4 locations
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: 2 locations
Frontline Immunotherapy Combined with Radiation and Chemotherapy in High Risk Endometrial Cancer, FIERCE Study
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
Comparison of Acute Toxicities between Patients Treated with Protons or Intensity Modulated Radiation Therapy after Surgery for the Treatment of Endometrial or Cervical Cancer
Status: Active
Location: 2 locations
Selective Surgical Staging versus Reflex Lymphadenectomy in Evaluating Sentinel Lymph Nodes in Non-mappers Undergoing Surgery for Endometrial Cancer
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Status: Active
Location: 2 locations
Reiki Therapy to Improve Symptoms Associated with Brachytherapy in Patients with Gynecological Malignancies, Reiki-Brachy Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Status: Active
Location: 4 locations
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Status: Active
Location: 2 locations
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Status: Active
Location: 3 locations
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York